Amifampridine Phosphate + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lambert Eaton Myasthenic Syndrome
Conditions
Lambert Eaton Myasthenic Syndrome
Trial Timeline
Jun 1, 2011 → Jul 1, 2016
NCT ID
NCT01377922About Amifampridine Phosphate + Placebo
Amifampridine Phosphate + Placebo is a phase 3 stage product being developed by Catalyst Pharmaceuticals for Lambert Eaton Myasthenic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01377922. Target conditions include Lambert Eaton Myasthenic Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02562066 | Phase 3 | Completed |
| NCT01377922 | Phase 3 | Completed |
Competing Products
1 competing product in Lambert Eaton Myasthenic Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Amifampridine Phosphate + Placebo Oral Tablet | Catalyst Pharmaceuticals | Phase 3 | 72 |